Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21869174 | 0.99 | SLC10A1 (0.47) | SLC10A1MAPK1 | |
| SCHEMBL21868867 | 0.97 | SLC10A1 (0.50) | SLC10A1 | |
| SCHEMBL21869113 | 0.88 | SLC10A1 (0.48) | SLC10A1 | |
| SCHEMBL21869137 | 0.86 | SLC10A1 (0.46) | SLC10A1MAPK1 | |
| SCHEMBL21869207 | 0.86 | SLC10A1 (0.45) | SLC10A1MAPK1 | |
| SCHEMBL21868864 | 0.84 | HTR2B (0.49) | SLC10A1 | |
| SCHEMBL21869142 | 0.83 | SLC10A1 (0.54) | SLC10A1 | |
| SCHEMBL21868895 | 0.83 | SLC10A1 (0.54) | SLC10A1 | |
| SCHEMBL22646355 | 0.83 | SLC10A1 (0.54) | SLC10A1 | |
| SCHEMBL21869535 | 0.83 | SLC10A1 (0.46) | SLC10A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591334-B2 | Substituted pyrrolizines for the treatment of hepatitis B | SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO., LTD. (CN) | 2023-02-28 | — | — | US | disclosed |
| US-20200354366-A1 | BICYCLIC NUCLEOCAPSID INHIBITOR AND USE OF SAME AS DRUG IN TREATMENT OF HEPATITIS B | SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO., LTD. (CN) | 2020-11-12 | — | — | US | disclosed |
| EP-3628674-A1 | BICYCLIC NUCLEOCAPSID INHIBITOR AND USE OF SAME AS DRUG IN TREATMENT OF HEPATITIS B | Shanghai Longwood Biopharmaceuticals Co., Ltd. (CN) | 2020-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591334-B2 | Substituted pyrrolizines for the treatment of hepatitis B | SLC10A1, NUP188, NR1H4 | SLC10A1 1/4885MAPK1 1633/4885 |
| US-20200354366-A1 | BICYCLIC NUCLEOCAPSID INHIBITOR AND USE OF SAME AS DRUG IN TREATMENT OF HEPATITIS B | SLC10A1, NR1H4, NUP188 | SLC10A1 1/4885MAPK1 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.